According to one expert at Pitchbook, two core issues are likely to dominate healthcare reform discussions in 2026: rising costs and flaws in Medicare Advantage. Healthcare affordability remains a ...

Across the healthcare industry, patients are demanding more transparency. They want control over their health and access to their healthcare data. And they’re right – patients should be at the center ...

New research emerged this month shining light on the need for wider use of continuous glucose monitors (CGMs). The study — which was conducted by CCS, a chronic care management company — analyzed data ...

PCR is a mainstay in diagnostics, but whether a sample is collected at a clinic or at home, such tests require sending a sample to a lab and then waiting for results. A new FDA authorized ...

The process of accurately identifying eligible patients for clinical trials has been a major bottleneck for decades. Medical records are messy, and diagnosis codes often reflect billing needs rather ...

HHS proposed changes that would roll back many Biden-era policies, eliminate most health tech certification criteria,and ...

New research suggests that health systems are struggling to effectively use AI to improve patient engagement. The study, released earlier this month, found that while investments in tools like ambient ...

In a Friday letter, a group of pharmacy organizations called on Congressional leadership to take action on pharmacy benefit manager reform. The organizations included in the letter are the National ...

Evvy, a women’s health startup, has launched an at-home test for urinary tract infection (UTI), the company announced Tuesday. New York City-based Evvy is a direct-to-consumer company. Its flagship ...

A new startup focused on helping people live longer, healthier lives emerged from stealth on Tuesday. The company, called Hundred Health, integrates users’ health data, including their medical history ...

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...